glycosidase-in-1

Glycosidase-IN-1 is a glycosidase inhibitor synthesized from D-mannose with hypoglycemic activity. It can be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors.

β-glycosidase-IN-1 is a piperidine derivative, and is an inhibitor of β-glycosidase. It has hypoglycemic activity.

α-Glycosidase-IN-1 (compound MZ7) is a potent inhibitor of α-GLY (α-glycosidase) (IC50: 44.72 nM, Ki: 44.74 nM). α-Glycosidase-IN-1 also inhibits human carbonic anhydrase isozymes I and II (hCA I and hCA II) and acetylcholine esterase (AChE), with IC50 values of 104.87, 100.04 and 654.87 nM, respectively. The IC50 values for α-Glycosidase-IN-1 are 104.87, 100.04 and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used in the study of diabetes, Alzheimer's disease, ulcers, heart failure, epilepsy and many other diseases.

Peptide-N-Glycosidase F (PNGase F), an asparagine amidase, catalyzes the detachment of N-linked oligosaccharides from the innermost GlcNAc to asparagine residues within high mannose, hybrid, and complex oligosaccharides of glycoproteins. This enzyme is instrumental in the structural and functional analysis of glycoproteins [1].

PNGase F, a glycosidase, catalyzes the cleavage of an internal glycoside bond in an oligosaccharide. PNGase F removes nearly all N-linked oligosaccharides from glycoproteins [1] [2] .

Endoglycoceramidase I (EGCase I), a glycosidase frequently utilized in biochemical studies, catalyzes a transglycosylation reaction. This process involves transferring the sugar moiety of GSLs to the primary hydroxyl group of various 1-alkanols [1].